The Next Frontier for Biosimilars Intrusion

Posted by Will Gatziolis on Jul 25, 2019 8:00:00 AM

Eric Detwiler, Sandeep Sangwan and Christina Corridon co-wrote this blog post with Will Gatziolis.

As of mid-2019, the U.S. market has seen considerable competition from biosimilars in supportive oncology care. The next U.S. biosimilar frontier is therapeutic oncology care, where Genentech’s big trio—Rituxan, Herceptin and Avastin—will likely attempt to hold their ground against biosimilars. Reference product manufacturers and biosimilar manufacturers have been closely monitoring U.S. biosimilar uptake to understand how this market is likely to evolve, but diverse go-to-market and defense strategies may leave us with more questions than answers. As pricing pressure mounts in the U.S., so does pressure on biosimilar uptake, leaving reference product manufacturers and biosimilar manufacturers alike wondering what biosimilar uptake will look like in the therapeutic oncology space, and how much price erosion can be expected due to biosimilar competition.


>
Read More

Biosimilars in Action at ASH 2018

Posted by Prateek Yadav on Dec 21, 2018 9:12:11 AM

Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.

At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.

Here are our top three takeaways from this year’s event:


>
Read More

Preparing for the First Wave: Biosimilars at ASCO 2018

Posted by Max Kuehn on Sep 5, 2018 8:00:00 AM

As always, clinical innovation dominated the conversation at ASCO 2018, but many attendees also made time to attend sessions on value and financial burden, where biosimilars were a frequent topic. With more than 40 biosimilars already approved in the EU, and rituximab, trastuzumab and bevacizumab biosimilars approaching launch in the U.S., biosimilars will play a major role in the future oncology landscape. 


>
Read More

Getting a Read on the EU’s Biosimilar Uptake Across Therapeutic Areas

Posted by Christina Corridon on May 31, 2018 8:00:00 AM

Laura Nielsen co-authored this blog post with Christina Corridon. 

Since the first EU biosimilar approval for Sandoz’s Omnitrope 12 years ago, the European biosimilar market has been difficult to predict. The dynamic policy and regulatory environment, differing levels of payer control, and variability in go-to-market approaches and manufacturing necessitate a bit of guesswork when it comes to predicting how a given biosimilar will perform. 


>
Read More

A New Era of Biosimilars in Oncology: Four Themes From ESMO 2017

Posted by Christina Corridon on Sep 21, 2017 12:30:53 PM

The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.

At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:


>
Read More